Gastrointestinal Cytoprotection by PPAR𝛾 Ligands

Table 2

Cytoprotective properties of PPAR𝛾 in experimental model of the intestinal inflammation.

Model	PPAR𝛾 ligand	References
Ischemia/reperfusion injury	Rosiglitazone	Nakajima et al. [18]
	Pioglitazone	Naito et al. [25]
	15d-PGJ2	Cuzzocrea et al. [26]
DSS colitis	Troglitazone	Su et al. [27]
	Rosiglitazone	Saubemann et al. [28]
	Pioglitazone	Takagi et al. [29], Schaefer et al. [30]
	CLA	Bassaganya-Riera et al. [31]
TNBS colitis	Troglitazone	Desreumaux et al. [32]
	Rosiglitazone	Sánchez-Hidalgo et al. [33]
	Pioglitazone	Schaefer et al. [30]
	5-ASA	Rousseaux et al. [34]
CD4+CD45RBhigh (transfer colitis model)	CLA	Bassaganya-Riera et al. [31]
IL-10 KO (genetic colitis model)	Rosiglitazone	Lytle et al. [35]
SAMP1/YitFC (spontenouse colitis model)	Rosiglitazone	Sugawara et al. [36]

DSS, dextran sodium sulphate; TNBS, 2,4,6-trinitrobenzene sulfonic acid; 15dPGJ2, 15-deoxy-D12,14-prostaglandin J2; CLA, conjugated linoleic acid; 5-ASA, 5-aminosalycilic acid; IL-10 KO, interleukin 10 knockout mice.